Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258998 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL6464207 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL8117010 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL60323 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL2279600 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL17061382 | 0.98 | TDP1 (0.66) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL60713 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL13893402 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL421756 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL426635 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736666-A1 | NUTRIENT COMPOSITION FOR ANIMALS | Racehorse Incorporated (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-20260096577-A1 | ANIMAL NUTRITIONAL COMPOSITION | RACEHORSE INCORPORATED (JP) | 2026-04-09 | — | — | US | disclosed |
| US-20260027144-A1 | ENTERIC CAPSULE FOR IMPROVING INTESTINAL BACTERIAL FLORA ENCAPSULATING NICOTINAMIDE MONONUCLEOTIDE | TANAKA MEGUMI (JP) | 2026-01-29 | — | — | US | disclosed |
| US-20250205266-A1 | AGENT FOR ORAL DISEASES | MIRAILAB BIOSCIENCE INC. (JP) | 2025-06-26 | — | — | US | disclosed |
| EP-4559327-A1 | ENTERIC CAPSULE FOR IMPROVING INTESTINAL BACTERIAL FLORA ENCAPSULATING NICOTINAMIDE MONONUCLEOTIDE | Tanaka, Megumi (JP) | 2025-05-28 | — | — | EP | disclosed |
| CN-119584872-A | Enteric capsule preparation filled with nicotinamide mononucleotide for improving intestinal flora | 田中惠 | 2025-03-07 | — | — | CN | disclosed |
| WO-2025033134-A1 | INFLAMMATORY CYTOKINE EXPRESSION INHIBITOR AND METHOD FOR INHIBITING EXPRESSION OF INFLAMMATORY CYTOKINE | ミライラボバイオサイエンス株式会社 | 2025-02-13 | — | — | WO | disclosed |
| EP-4494485-A1 | AGENT FOR ORAL DISEASES | Mirailab Bioscience Inc. (JP) | 2025-01-22 | — | — | EP | disclosed |
| WO-2025004279-A1 | NUTRIENT COMPOSITION FOR ANIMALS | 株式会社レースホース | 2025-01-02 | — | — | WO | disclosed |
| EP-4454656-A1 | LIQUID COMPOSITION AND COMPOSITION FOR ACTIVATING SIRTUIN | Dream Power Incorporated (JP) | 2024-10-30 | — | — | EP | disclosed |
| EP-3578639-A1 | AGENT FOR ACCELERATING GROWTH OF STEM CELLS WITH DIFFERENTIATION POTENTIAL | Oriental Yeast Co., Ltd. (JP) | 2019-12-11 | — | — | EP | disclosed |
| WO-2019182044-A1 | DIFFERENTIATION PROMOTER FOR PLURIPOTENT STEM CELLS | オリエンタル酵母工業株式会社 | 2019-09-26 | — | — | WO | disclosed |
| EP-3513796-A1 | SLEEP DISORDER IMPROVEMENT AGENT AND METHOD FOR IMPROVING SLEEP DISORDERS | Tanaka, Megumi (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-3513795-A1 | VISUAL FUNCTION IMPROVEMENT AGENT, AND METHOD FOR IMPROVING VISUAL FUNCTION | Tanaka, Megumi (JP) | 2019-07-24 | — | — | EP | disclosed |
| WO-2019078177-A1 | COSMETIC COMPOSITION COMPRISING NICOTINAMIDE MONONUCLEOTIDE | 田中 めぐみ | 2019-04-25 | — | — | WO | disclosed |
| US-8481711-B2 | Neurite outgrowth agent | Hidenori Kamanishi (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20130102771-A1 | NEURITE OUTGROWTH AGENT | Hidenori KAMINISHI | 2013-04-25 | — | — | US | disclosed |
| WO-1998039347-A3 | SYNTHESIS OF L-RIBOSE AND 2-DEOXY L-RIBOSE | UNIV CALIFORNIA (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998039347-A2 | SYNTHESIS OF L-RIBOSE AND 2-DEOXY L-RIBOSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039347-A2 | SYNTHESIS OF L-RIBOSE AND 2-DEOXY L-RIBOSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027144-A1 | ENTERIC CAPSULE FOR IMPROVING INTESTINAL BACTERIAL FLORA ENCAPSULATING NICOTINAMIDE MONONUCLEOTIDE | SI, SIRT1, NNT | TDP1 4719/4885ABCB1 3516/4885POLB 2984/4885 |
| US-20250205266-A1 | AGENT FOR ORAL DISEASES | NAMPT, NNT, NAPRT | TDP1 3369/4885ABCB1 2561/4885POLB 1058/4885 |
| US-20260096577-A1 | ANIMAL NUTRITIONAL COMPOSITION | NAMPT, NNT, NADK | TDP1 4533/4885ABCB1 4853/4885POLB 1893/4885 |
| US-20130102771-A1 | NEURITE OUTGROWTH AGENT | NGF, BDNF, NAMPT | TDP1 1053/4885ABCB1 4821/4885POLB 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.